2Q19—Biotech funding stagnates

Access optionsAccess options Subscribe to JournalGet full journal access for 1 year$250.00only $20.83 per issueSubscribeAll prices are NET prices. VAT will be added later in the checkout.Rent or Buy articleGet time limited or full article access on ReadCube.from$8.99Rent or BuyAll prices are NET prices.Additional access options:Log inOpenAthensShibbolethLearn about institutional subscriptions Author informationAffiliationsSenior Editor, Nature BiotechnologyLaura…

3 Reasons Why Amgen Could Actually Acquire Alexion

Rumors that Amgen plans to buy Alexion might not become reality. But a deal would make a lot of sense. Is a major biotech buyout in the works? Spanish television network Intereconomia recently reported that Amgen (NASDAQ:AMGN) is in discussions to acquire Alexion Pharmaceuticals (NASDAQ:ALXN). Intereconomia cited unnamed sources that said a deal could be…

2 Top Stocks to Buy in August

Adverum Biotechnologies and Catalyst Pharmaceuticals could both post sizable gains next month. Summer is rarely kind to biotech stocks. However, this class of equities often starts to regain its footing in the month of August, thanks to a bevy of earnings reports.  Which biotech stocks are in the best position for a strong August? The…

Why Sarepta Therapeutics Stock Tanked on Thursday

Its high-profile DMD gene-therapy candidate hit an unexpected stumbling block. What happened Sarepta Therapeutics (NASDAQ:SRPT), a midcap biotech specializing in the development of treatments for rare diseases, saw its shares plunge by a whopping 12.6% on Thursday before trading was halted at approximately 12:30 p.m. Trading resumed just before the close, and shares finished down…

Promising approach to reducing plaque in arteries

In a new Yale-led study, investigators have revealed previously unknown factors that contribute to the hardening of arteries and plaque growth, which cause heart disease. Their insight is the basis for a promising therapeutic approach to halt and potentially reverse plaque buildup and the progression of disease, the researchers said. The study was published online…

Young blood cocktail stops Alzheimer’s decline, early clinical trial reports

Alkahest, a California-based biotech start-up, has just revealed some compelling early results from an ongoing Phase 2 trial into the efficacy of its novel formulation of plasma proteins derived from young blood, developed to slow, or even stop, the cognitive decline associated with Alzheimer’s disease.The idea of young blood holding a magical kind of rejuvenating…

Tech Explained: CRISPR gene editing

CRISPR works by allowing scientists to quickly and cheaply cut out and replace very specific sections of DNA, such as those responsible for certain diseases. | Photo source Pixabay Science & Environment What is CRISPR and how is it changing the face of gene editing? Can you imagine being able to quickly and cheaply edit…

Govt to soon consider relaxing FDI norms in single brand, digital media

The government will soon consider relaxing foreign direct investment (FDI) norms in several sectors, including single-brand retail trading and digital media, to attract overseas players, sources said.Other sectors where FDI rules would be eased are coal and contract manufacturing.According to sources, the Union Cabinet would soon consider these issues for approval.The government may allow 100…